With its center of operations in India, Anuva is supported by the Center for Bioinformatics at Cambridge in the UK. The company also claims that it is creating the most diverse genomic bio/data bank of the Asian population to be used for research and development in the global pharmaceutical sector.
As per reports in PTI, the knowledge gained and generated by Anuva on health and disease will be directly applicable to the treatment. This would be particularly beneficial to diverse under-represented populations. It will be able to accelerate drug discovery by identifying novel targets and pathways with the underlying mission of “providing better health for all”.
With the tie-up with Helix, the company can leverage the genomics giant’s deep expertise in sequencing technology and translational research.